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Abstract 
Introduction: Numerous semaphorins have been widely clarified to be involved in the development of multiple cancers. However, sema-
phorin 6B (SEMA6B) has not yet been extensively reported in cancers, especially in thyroid carcinoma.
Material and methods: Thyroid carcinoma RNA-Seq dataset from the TCGA database was used to assess the expression of SEMA6B in 
tissues, as well as its clinical significance. We adopted qRT-PCR and western blot analyses to measure the mRNA and protein expression 
of SEMA6B in thyroid carcinoma cells. The biological roles of SEMA6B in thyroid carcinoma cells were examined through cell counting 
kit 8, clone formation, and Transwell assays. Also, GSEA was used to identify the gene sets modulated by SEMA6B, which is further veri-
fied by western blot.
Results: According to the public dataset from the TCGA database, we found that the expression of SEMA6B was upregulated in thyroid 
carcinoma tissues compared to adjacent non-tumour tissues, and a high level of SEMA6B resulted in a poorer prognosis compared to 
the low-level SEMA6B group. Functional experiments showed that silencing SEMA6B suppressed the B-CPAP cells viability, invasive-
ness, and motility, whereas up-regulating SEMA6B in FTC-133 cells led to opposite outcomes. Furthermore, knockdown of SEMA6B in 
B-CPAP cells could significantly elevate the protein expression of NUMB and reduce the expression of NOTCH1, HES1, and Cyclin D1. 
Conversely, overexpression of SEMA6B in FTC-133 cells presented opposite results on the protein expression of these Notch signalling 
pathway-related markers.
Conclusions: Our findings demonstrated that SEMA6B exerts a tumourigenic effect in thyroid carcinoma partly by activating Notch 
signalling pathway, which provides a possible biomarker for the therapeutic intervention in thyroid carcinoma. (Endokrynol Pol 2021; 
72 (1): 29–36)
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Introduction
Thyroid carcinoma is a common malignant tumour in 
endocrine gland, which accounts for 94.5% of all endo-
crine tumours [1, 2]. Statistics showed that the incidence 
of thyroid carcinoma is on the rise worldwide [3, 4]. An 
American cancer report in 2019 estimated that there 
were 52,070 new cases of thyroid carcinoma, which 
ranks as the sixth most common malignancy in women 
[5]. In China, the national central cancer registry col-
lected data from 449 registries across the country in 2014 
and found that thyroid carcinoma ranked fourth among 
new malignancies in women [6]. The histopathological 
types of thyroid carcinoma includes follicular, poorly 
differentiated, papillary, anaplastic, and medullar 
thyroid carcinomas [7]. Among these types, papillary 
thyroid carcinoma is the most common, accounting for 
more than 80% of thyroid carcinomas [8]. Differentiated 
thyroid carcinomas (including papillary and follicular) 
have a low degree of malignancy and a good response 
to treatment [9]. However, some thyroid carcinomas 
with low differentiation or metastasis are still difficult 
to treat, showing the malignant characteristics of rapid 
tumour growth, high incidence of lymphatic metastasis, 
insensitivity to iodine treatment, and postoperative 
recurrence and metastasis [10]. Noticeably, a study re-
ported that 67.9% of classic papillary thyroid carcinoma 
cases present with lymph node metastasis, which shows 
a higher recurrence rate and a higher disease-specific 
mortality compared with the intra-thyroid group [11, 
12]. Therefore, early identification of papillary thyroid 
carcinoma and investigation of its potential mechanism 
are of great significance for the formulation of clinical 
comprehensive treatment plans and improvement of 
prognosis of papillary thyroid carcinoma patients.
Semaphores are a large family of secretory proteins 
and membrane-bound glycoproteins initially character-
ised as axonal guidance and neurodevelopment factors 
[13]. In recent years, in addition to being implicated in 
neural activity, semaphoring molecules have also been 
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Transfection
Lipofectamine2000 (Invitrogen) was used following the manufac-
ture’s protocol. Two small interference RNAs (si-RNAs) targeting 
SEMA6B (si-SEMA6B-1: 5’-CCTAGCCATTGATGCTGTCAT-3’, 
si-SEMA6B-2: 5’-CCGGATGACATCCTCAACTTT-3’) were used 
to perform the loss-of-function of SEMA6B assay, and a scramble 
siRNA (si-con: 5’- CGAACUCACUGGUCUGACC -3’) was used as 
negative control (NC). Plasmid pcDNA3.1-SEMA6B was used to 
implement the gain-of-function of SEMA6B assay, and pcDNA3.1 
empty vector served as NC. All the siRNAs and plasmids were 
synthesised from the Shanghai GeneChem Corporation (China).
Quantitative Reverse-Transcription PCR
Total RNA was extracted from cultured cells using an Ultrapure 
RNA kit (ComWin Biotech, CWBIO, Beijing, China) and reverse 
transcribed to cDNA using the HiFiScript cDNA Synthesis Kit 
(CWBIO). The mRNA level of SEMA6B was measured by UltraSYBR 
Mixture (CWBIO). Primers are listed below:
 — SEMA6B F: 5’-GTCGGAGACAACATCAGCGGTA-3’,
 — SEMA6B R: 5’-GCATCAATGGCTAGGAAGTCGG-3’;
 — GAPDH F: 5’-TGTGTCCGTCGTGGATCTGA-3’,
 — GAPDH R: 5’-CCTGCTTCACCACCTTCTTGA-3’.
Relative mRNA level of SEMA6B was evaluated using the compara-
tive Ct value and normalised to GAPDH.
Western blot
Total proteins were extracted using RIPA buffer (CWBIO) with 
proteinase inhibitor from cells after transfection for 24 h and 
quantified using the bicinchoninic acid disodium assay. Then, 20 
μg of proteins were loaded onto 10% SDS-PAGE and transferred 
onto PVDF membrane. Upon blocking with 5% non-fat dried milk 
for an hour, the membrane was subjected with primary antibod-
ies anti-SEMA6B (PA5-47251, Invitrogen, Carlsbad, CA, USA), 
anti-NUMB (PA5-81233, Invitrogen), anti-NOTCH1 (PA5-32522, 
Invitrogen), anti-HES1 (PA5-28802, Invitrogen), anti-Cyclin D1 
(MA5-16356, Invitrogen), and GAPDH rabbit polyclonal antibody 
(PA1-16777, Invitrogen) at 4°C for 24 hours. After rinsing three 
times with TBST, the membranes were subjected with horseradish 
peroxidase-labelled secondary antibodies for an hour. The labelled 
bands were determined using SuperSignal chromogenic reagent 
kit (Beyotime, Nantong, China) and quantified by Image J 1.44 
software (NIH, Bethesda, MD, USA).
Cell proliferation assay
For cell counting kit 8 (CCK8) assay, transfected B-CPAP and FTC-
133 cells at a density of 0.1 × 104 cells/well were seeded in each well 
of 96-well plates and incubation for 72 hours. At the points of 0 h, 
24 h, 48 h, and 72 h, 10 μL CCK8 reagent (Beyotime) was added to 
each well and cultured for another 1.5 h. The optical density (OD) 
value was determined using an Elx800 Reader (Bio-Tek, Winooski, 
VT, USA) according to the manufacturer’s instructions.
For clone formation assay, transfected cells (500 cells/dish) were 
seeded in a 60 mm dish and cultured at 37°C with 5% CO2 for 
1–2 weeks until cells formed sufficiently large colonies. Then, the 
colonies were fixed with 5 ml 4% paraformaldehyde for 30 minutes 
and stained with 0.1% crystal violet for 20 minutes. After air-drying, 
colonies were manually counted and photographed.
Cell invasion and migration assay
Transwell invasion and migration assay was conducted using 
24-well Transwell plates (Corning Inc., Corning, NY, USA) with 
or without Matrigel-coated membrane, respectively. Transfected 
cells (1 × 104 for invasion assay and 0.5 × 104 for migration assay) 
suspended in 100 μl serum-free RPMI-1640 medium were seeded 
into the upper compartment, while 500 μl RPMI-1640 plus 10% FBS 
was filled in the lower compartment. Upon cultivation at 37°C for 
24 h, cells that had invaded or migrated through the 8-μm pores 
implicated in immune response and angiogenesis [14]. 
Also, increasing evidence has revealed that semaphores 
play a crucial role in the progression of tumours and 
are expected to be potential therapeutic bio-markers 
in various tumours [15]. The family of semaphores is 
divided into eight subtypes and contains more than 30 
semaphore molecules of which subclasses 3-7 contain 
the 22 vertebrate semaphorins [16]. Class 6 Semaphorin 
B (SEMA6B) is a transmembrane protein belonging to 
the semaphorin family, which has been reported to 
participate in the progression of some cancers [17, 18]. 
It has been shown that SEMA6B levels were markedly 
elevated in gastric tumour cells in comparison with 
normal control cells, and silencing SEMA6B notably 
inhibited the cell invasion, migration, and adhesion in 
gastric cancer [17]. But in breast cancer tissues, 94% of 
cancer tissues presented a lower expression of SEMA6B 
compared to the median value of normal tissues [18]. 
These two different kinds of findings illustrate that 
SEMA6B might play different roles in the progression 
of different tumours. But its role in thyroid carcinoma 
is still poorly understood. 
The objective of this report was to examine the 
prognostic role of SEMA6B in thyroid carcinoma on the 
basis of the public database and to evaluate the effect 
of SEMA6B on the phenotype of thyroid carcinoma 
cells by in vitro experiments, as well as its influence 
on the Notch signalling pathway-related markers. All 
the data indicated that SEMA6B presents a prognostic 
value in thyroid carcinoma and may have the potential 




The data for 568 cases including 510 thyroid carcinoma samples 
and 58 adjacent normal samples were retrieved from the RNA-Seq 
dataset of the TCGA (https://cancergenome.nih.gov/) database and 
were used for bioinformatics analysis. 
Kaplan-Meier methods were used to evaluate the correlation be-
tween SEMA6B and the overall survival, which was compared by 
log-rank tests. The relevance between SEMA6B and clinical features 
was analysed using the chi-squared test.
Cell culture
The human papillary thyroid carcinoma cell lines B-CPAP and FTC-
133 were acquired from the Shanghai Chinese Academy of Sciences 
cell bank. The normal thyroid epithelial cells – Nthy-ori 3-1 – were 
acquired from European Collection of Cell Culture (Salisbury, UK). 
These three types of cells were incubated in RPMI-1640 medium 
(Beyotime, Jiangsu, China) supplemented with 10% foetal bovine 
serum (FBS) and antibiotics including penicillin (100 U/ml) and 
streptomycin (0.1 mg/ml) under a humidified atmosphere of 5% 
CO2 at 37°C.
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were rinsed with PBS, fixed using paraformaldehyde, and stained 
by crystal violet. Next, the number of invaded and migrated cells 
was counted in five representative fields under light microscopy 
(40× magnification) and photographed.
Statistical analyses
All the statistical analyses were adopted using GraphPad Prism 
6.0 software (San Diegl, CA, USA) and SPSS 22.0 software (IBM 
SPSS, Armonk, NY, USA). Differences between two groups was 
determined by unpaired Student’s t test, and the differences 
between multiple groups were compared by one-way analysis of 
variance (ANOVA) followed a post hoc test. All the experiments 
were conducted in triplicate. A p value of less than 0.05 was defined 
as statistical significance.
Results
SEMA6B expression is elevated in thyroid 
carcinoma and leads to a poor prognosis
To get an overview of SEMA6B status in thyroid car-
cinoma, we first analysed the expression of SEMA6B 
in the RNA-Seq dataset of thyroid carcinoma from 
the TCGA database and observed that SEMA6B was 
significantly upregulated in thyroid carcinoma tis-
sues in comparison with the adjacent non-tumour 
tissues (p < 0.0001, Fig  1A). Next, we selected two 
commonly used thyroid carcinoma cell lines to detect 
the mRNA level of SEMA6B by qRT-PCR. Consistent 
with the SEMA6B expression in tissues, the mRNA 
levels of SEMA6B were obviously elevated in thyroid 
carcinoma cells in contrast to normal thyroid epithelial 
cells (p < 0.01, Fig. 1B), suggesting that the upregulated 
SEMA6B might be involved in the development of 
thyroid carcinoma.
Next, to determine the clinical significance of 
SEMA6B in thyroid carcinoma, we evaluated the cor-
relation between SEMA6B and clinical characteristics 
based upon the public dataset from the TCGA database. 
The data were divided into high and low groups accord-
ing to the median expression of SEMA6B and showed 
that SEMA6B expression had a significant correlation 
with pathologic metastasis (M) (p < 0.05, Tab. 1), in-
dicating that SEMA6B might play a role in promoting 
metastasis in thyroid carcinoma. Kaplan-Meier method 
revealed that low SEMA6B expression has a higher 
probability of a better overall survival rate compared to 
the high SEMA6B expression group (p < 0.01, Fig. 1C). 
A B C
Figure 1. mRNA levels of SEMA6B in thyroid carcinoma and survival curve. A. SEMA6B expression in thyroid carcinoma tissues 
and the adjacent non-tumour tissues in the thyroid carcinoma RNA sequencing dataset from the TCGA database. B. QRT-PCR analysis 
of mRNA level of SEMA6B in malignant thyroid carcinoma B-CPAP and FTC-133 cells by comparison with non-malignant thyroid 
epithelial Nthy-ori 3-1 cells. **p < 0.01, compared with Nthy-ori 3-1. C. The overall survival curve was plotted by Kaplan-Meier 
methods based upon the expression of SEMA6B in thyroid carcinoma patients in the TCGA cohort
Table 1. Correlation between clinical features of thyroid 
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All these data illustrated that SEMA6B may be a useful 
bio-target for the diagnosis and prognosis of thyroid 
carcinoma.
SEMA6B enhances cell viability in thyroid 
carcinoma
To better understand the biological functions of SEMA6B 
in thyroid carcinoma cells, we implemented CCK8 and 
clone formation assays to detect the cell viability after 
altering the expression of SEMA6B. Before detecting, 
we established B-CPAP cells with depleted SEMA6B 
using siRNA targeting SEMA6B and FTC-133 cells with 
overexpressed SEMA6B using pcDNA3.1-SEMA6B. The 
expression of SEMA6B was measured using qRT-PCR 
and western blot analyses. The data revealed that the 
mRNA and protein expression of SEMA6B was nota-
bly reduced upon knockdown of SEMA6B, whereas 
SEMA6B expression was dramatically elevated after 
overexpression of SEMA6B compared to their respec-
tive controls (p < 0.01, Fig. 2). For the loss-of-function 
of SEMA6B, si-SEMA6B-1 was more efficient, so it was 
selected to perform the further knockdown tests. The 
CCK8 assays demonstrated that knockdown of SEMA6B 
led to an impaired proliferation in B-CPAP cells in 
comparison with the si-con group (p < 0.05, Fig. 3A); 
however, the enhanced expression of SEMA6B resulted 
in an elevated proliferation in FTC-133 cells in contrast 
to the pcDNA3.1 empty vector group (p < 0.01, Fig. 3B). 
Additionally, the significant difference of the knock-
down and overexpression tests first appeared at the 24 h 
and 48 h points, respectively. The effects of SEMA6B on 
the cell viability were also confirmed by clone formation 
assay, which indicated that the colony-forming capacity 
was dramatically reduced in B-CPAP cells with depleted 
SEMA6B (p < 0.01, Fig. 3C–D), while overexpression of 
SEMA6B drastically increased the number of colonies 
in FTC-133 cells (p < 0.01, Fig. 3E–F). Collectively, all 
these results illustrated that SEMA6B exerts a pro-pro-
liferative effect in thyroid carcinoma cells.
SEMA6B promotes cell invasion and migration 
in thyroid carcinoma
To examine the potential effect of SEMA6B on the inva-
siveness and motility, Transwell assay was implement-
ed. As shown in Figure 4A, silencing SEMA6B inhibited 
the invasive and migratory capacities of B-CPAP cells 
by comparison to the si-con group (p < 0.01, Fig. 4A–B). 
On the other hand, upregulating SEMA6B enhanced 
the invasive and migratory abilities of FTC-133 cells 
in contrast to the vector group (p < 0.01, Fig. 4C–D). 
Taken together, these observations demonstrated that 
SEMA6B could affect the cell invasion and migration 
in thyroid carcinoma.
SEMA6B activates the Notch pathway
Studies have shown that the Notch pathway is involved 
in the regulation of the recurrence and development of 
a variety of tumours, and it plays a role in synergistic 
or antagonistic way [19]. In our work, GSEA revealed 
that high level of SEMA6B positively correlated with 
the Notch signalling pathway (p < 0.01, Fig.  5A). 
Thus, to verify the correlation between SEMA6B and 
Notch pathway, we detected the protein expression 
of Notch signalling-related markers, including an-
tagonist NUMB, NOTCH1, downstream target HES1, 
and growth-promoting gene Cyclin D1, by gain- and 
loss-of-function of SEMA6B assays. The data showed 
that, compared to the si-con group, silencing SEMA6B 
significantly elevated the expression of NUMB and 
reduced the expression of NOTCH1, HES1, and Cyclin 
D1 (p < 0.01, Fig. 5B and C). Conversely, overexpres-
sion of SEMA6B resulted in a dramatic decrease in the 
A B
C D
Figure 2. Transfection efficiency of loss- and gain-of-function of 
SEMA6B. A. C. Detection of transfection efficiency in B-CPAP 
cells which were treated with si-con, si-SEMA6B-1, and si-
SEMA6B-2. B. D. Detection of transfection efficiency in FTC-133 
cells that were with pcDNA3.1 empty vector, pcDNA3.1- 
-SEMA6B. The expression of SEMA6B was determined using 
qRT-PCR (A, B) and western blot (C, D). **p < 0.01, compared 
with the si-con group or vector
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expression of NUMB but led to an obvious increase on 
the protein level of NOTCH1, HES1, and Cyclin D1 
(p < 0.01, Fig. 5B, D). Thus, we inferred that SEMA6B 
plays a promoting effect in thyroid carcinoma partly by 
activating the Notch signalling pathway.
Discussion
The proteins galectin-3, cytokeratin-19, and HBME-1 are 
the most studied and meaningful markers associated 
with thyroid carcinoma diagnosis and prognosis [20]. 
However, at present there is no specific and sensitive 
marker for papillary thyroid carcinoma. Therefore, 
more meaningful biomarkers associated with the 
development of papillary thyroid carcinoma need to 
be identified. Our work focused on the evaluation of 
the role of SEMA6B in the diagnosis and prognosis of 
thyroid carcinoma and the exploration of its functional 
roles, as well as the underlying mechanism, hoping to 
provide a possible marker for the therapy of thyroid 
carcinoma.
For semaphorins, the class 3 and 4 family mem-
bers have been well described in the progression of 
cancers. Numerous studies have clarified that some 
semaphorins, such as SEMA3F [21, 22] and SEMA3B 
[23], function as inhibitors to suppress tumour pro-
gression, while other semaphorins, such as SEMA4A 
[24], SEMA4D [25], SEMA5A [26], and SEMA6A [27], 
function as promoters to facilitate tumour progression. 
SEMA6B, a class 6 semaphorin, was first observed at 
a higher level in normal brain tissues and at a lower 
level in other tissues [28]. However, its role in cancers is 
rarely reported. In the current study, by bioinformatics 




Figure 3. Effects of SEMA6B on the cell viability in thyroid carcinoma. A, B. CCK8 assays were used to determine the OD values 
when silencing SEMA6B in B-CPAP cells (A) and upregulation of SEMA6B in FTC-133 cells (B). C–F. Clone formation assays 
were implemented to examine the cells colony-forming abilities when silencing SEMA6B in B-CPAP cells (C, D) and upregulation of 
SEMA6B in FTC-133 cells (E, F). (C, E) Representative colonies in dishes. (D, F) The number of colonies was quantified. **p < 0.01, 
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to be highly expressed in thyroid carcinoma and led to 
a poorer survival, hinting that SEMA6B may play a role 
in tumourigenesis in thyroid carcinoma. Consistent 
with these findings, the mRNA and protein levels of 
SEMA6B were also found to be higher in gastric can-
cer cell line SGC-7901 in contrast to normal cells. Im-
portantly, the functional experiments showed that 
inhibition of SEMA6B expression notably suppressed 
the gastric cancer cell invasion, migration, and adhe-
sion [17]. Coincidentally, using thyroid cells, we also 
found that SEMA6B could dramatically enhance the 
cell viability, invasiveness, and motility. Interestingly, 
the reduced expression of SEMA6B in breast cancer in 
contrast to healthy samples was frequently detected 
[18]. SEMA6B is not the only one showing this duality. 
Another member of class 6, SEMA6A, was reported to 
inhibit glioma cells proliferation, invasion, and migra-
tion [29], while its expression was elevated in several 
renal tumour tissues compared to adjacent normal tis-
sues [30]. The mechanisms responsible for this duality 
are not fully understood. One article explains that this 
may be the result of post-translational processing and 
the formation of complex associations between sema-
phorin receptors and other types of membrane-bound 
receptors [14]. However, further research is needed.
Abnormal Notch signalling pathway appears in 
many malignant tumours [31]. Thyroid carcinoma is 
no exception. Aberrant Notch pathway has been found 
to inhibit or promote tumour progression depending 
on the cell type and environment [32]. NOTCH1 is 
one of the four receptors of Notch signalling pathway, 
and its role in papillary thyroid carcinoma and related 
mechanisms are still controversial. At present, most 
scholars consider that NOTCH1 signalling pathway 
can promote papillary thyroid carcinoma cell prolif-
eration and metastasis, and is closely linked to worse 
prognosis. Piana et al. found that positivity of NOTCH1 
was predominantly correlated with papillary thyroid 
carcinoma by immunohistochemistry through a series 
of 106 thyroid specimens, suggesting that the progres-
sion of papillary thyroid carcinoma is positively cor-
related with the activation of NOTCH1 [33]. By GSEA 
analysis, we found that high expression of SEMA6B 
has a positive correlation with markers related to 
Notch signalling pathway, which raises the question 
of whether the growth- and invasive-promoting effects 
of SEMA6B in thyroid carcinoma are correlated with 
NOTCH1 protein. Moreover, NUMB as a Notch signal-
ling antagonist inhibits Notch signalling by stabilising 
the intracellular domain of NOTCH1 receptor, suggest-
ing that the expression of NUMB should be inversely 
proportional to the expression of SEMA6B [34]. In ad-
dition, as a downstream target gene of Notch pathway, 
HES1 transmits down Notch signal and can maintain 
a variety of immature cells in an undifferentiated state 
[35]. Also, studies have reported that the activation of 
A B
C D
Figure 4. Effects of SEMA6B on the cell invasiveness and motility in thyroid carcinoma. Transwell assays were implemented to 
determine the invasion and migration of B-CPAP cells with knockdown of SEMA6B (A, B) and FTC-133 cells with overexpression of 
SEMA6B (C, D). (A, C) Representative photographs of invasion and migration cells. (B, D) The number of invaded and migrated cells 
was quantified. **p < 0.01, compared with the si-con group or vector
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Notch pathway induces growth-promoting genes such 
as cyclin D1 to cause tumour formation, so we explored 
whether SEMA6B induces cyclin D1 to participate in the 
proliferation of thyroid carcinoma cells [36]. Western 
blot analysis revealed that silencing SEMA6B notably 
reduced the protein levels of NOTCH1, HES1, and 
cyclin D1, accompanied by an increase in HES1 protein 
expression, while overexpression of SEMA6B gave the 
opposite results. Therefore, it is reasonable to speculate 
that SEMA6B may play a tumourigenic effect in thyroid 
carcinoma by activating the Notch signalling pathway.
Conclusions
Taken together, the current study found that SEMA6B 
has a prognostic value in thyroid carcinoma and 
suggested that during the progression and tumou-
rigenesis of thyroid carcinoma, SEMA6B promoted 
the cell proliferation, migration, and invasion partly 
through regulating the Notch signalling pathway. 
These results highlight the potential of SEMA6B to 
be a target for the therapeutic intervention of thyroid 
carcinoma.
Figure 5. Correlation between SEMA6B and the Notch signalling relative proteins. A. GSEA analysis showed the enrichment of the 
Notch pathway-related markers in the high SEMA6B expression group based on the TCGA database. B. Protein levels of NUMB, 
NOTCH1, HES1, and Cyclin D1 in B-CPAP and FTC-133 cells after altering the expression of SEMA6B by western blot analysis. 
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